Chargement en cours...
Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients
The role of IgE autoantibodies has been demonstrated in the pathogenesis of bullous pemphigoid for many years. Recently, omalizumab (OMZ), a humanized monoclonal anti-IgE antibody that depletes total serum IgE, has been used off-label in a few case series of bullous pemphigoids demonstrating a rapid...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2022-04-01
|
| Collection: | Frontiers in Immunology |
| Sujets: | |
| Accès en ligne: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.874108/full |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|